

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/140144 A1

(51) International Patent Classification:

C12N 1/10 (2006.01) C12N 15/87 (2006.01)
C12N 15/64 (2006.01) C12N 15/90 (2006.01)
C12N 15/79 (2006.01) C12P 21/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/050173

(22) International Filing Date:

07 January 2021 (07.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/958,088 07 January 2020 (07.01.2020) US

(71) Applicant: **LIMMATECH BIOLOGICS AG** [CH/CH];
Grabenstr. 3, 8952 Schlieren (CH).

(72) Inventors: **MALLY, Manuela**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **FARIDMOAYER, Amirreza**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **SERVENTI, Fabio**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **FOLLADOR, Rainer**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH). **HARSMAN, Anke, Judith**; c/o LimmaTech Biologics AG Grabenstr. 3, 8952 Schlieren (CH).

(74) Agent: **JONES DAY LAW FIRM**; Prinzregentenstr. 11, 80538 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ENGINEERED LEISHMANIA CELLS

(57) Abstract: The present application relates to a method of recombinantly engineering a *Leishmania* cell that involves homologous recombination of DNA fragments. Further provided herein are *Leishmania* cells recombinantly engineered using the method provided herein. Also provided herein are methods of making a polypeptide using a *Leishmania* cell described herein and polypeptides produced by the methods provided herein.

WO 2021/140144 A1